E Ventre1, A Rozières1, V Lenief1, F Albert1, P Rossio2, L Laoubi1, D Dombrowicz3, B Staels3, L Ulmann4, V Julia2, E Vial2, A Jomard2, F Hacini-Rachinel2, J-F Nicolas1, M Vocanson1. 1. CIRI, International Center for Infectiology Research, Université de Lyon, INSERM, U1111, Ecole Normale Supérieure de Lyon, Centre International de Recherche en Infectiologie, Université Lyon 1, CNRS, UMR 5308, Lyon, France. 2. Nestlé Skin Health R&D, Sophia-Antipolis, Biot, France. 3. Université de Lille, INSERM, CHU de Lille, European Genomic Institute of Diabetes, Institut Pasteur de Lille, U1011-récepteurs nucléaires maladies cardiovasculaires et diabète, Lille, France. 4. Institut de Génomique Fonctionnelle, CNRS, INSERM, Université de Montpellier, Montpellier, France.
Abstract
BACKGROUND: Ivermectin (IVM) is widely used in both human and veterinary medicine to treat parasitic infections. Recent reports have suggested that IVM could also have anti-inflammatory properties. METHODS: Here, we investigated the activity of IVM in a murine model of atopic dermatitis (AD) induced by repeated exposure to the allergen Dermatophagoides farinae, and in standard cellular immunological assays. RESULTS: Our results show that topical IVM improved allergic skin inflammation by reducing the priming and activation of allergen-specific T cells, as well as the production of inflammatory cytokines. While IVM had no major impact on the functions of dendritic cells in vivo and in vitro, IVM impaired T-cell activation, proliferation, and cytokine production following polyclonal and antigen-specific stimulation. CONCLUSION: Altogether, our results show that IVM is endowed with topical anti-inflammatory properties that could have important applications for the treatment of T-cell-mediated skin inflammatory diseases.
BACKGROUND: Ivermectin (IVM) is widely used in both human and veterinary medicine to treat parasitic infections. Recent reports have suggested that IVM could also have anti-inflammatory properties. METHODS: Here, we investigated the activity of IVM in a murine model of atopic dermatitis (AD) induced by repeated exposure to the allergen Dermatophagoides farinae, and in standard cellular immunological assays. RESULTS: Our results show that topical IVM improved allergic skin inflammation by reducing the priming and activation of allergen-specific T cells, as well as the production of inflammatory cytokines. While IVM had no major impact on the functions of dendritic cells in vivo and in vitro, IVM impaired T-cell activation, proliferation, and cytokine production following polyclonal and antigen-specific stimulation. CONCLUSION: Altogether, our results show that IVM is endowed with topical anti-inflammatory properties that could have important applications for the treatment of T-cell-mediated skin inflammatory diseases.
Authors: Zaki F Aref; Shamardan Ezz Eldin S Bazeed; Mohammed H Hassan; Abeer S Hassan; Ali A Ghweil; Mennatallah Ali Abdelrhman Sayed; Alaa Rashad; Haggagy Mansour; Aida A Abdelmaksoud Journal: Infect Drug Resist Date: 2022-09-19 Impact factor: 4.177
Authors: Sandra Noack; John Harrington; Douglas S Carithers; Ronald Kaminsky; Paul M Selzer Journal: Int J Parasitol Drugs Drug Resist Date: 2021-04-27 Impact factor: 4.077
Authors: Hamzah A Alghamdi; Mohammed Al-Zharani; Nada H Aljarba; Abdullah A Alghamdi; Abdulrahman A Alghamdi; Badr A Aldahmash; Doaa M Elnagar; Saad Alkahtani Journal: Saudi Pharm J Date: 2022-06-28 Impact factor: 4.562
Authors: Daniel Kwesi Sia; Kwesi Boadu Mensah; Tony Opoku-Agyemang; Raphael D Folitse; David Obiri Darko Journal: BMC Vet Res Date: 2020-10-20 Impact factor: 2.741